Multi-modal proteomic analysis of retinal protein expression alterations in a rat model of diabetic retinopathy

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  VanGuilder, Heather D ^a   Bixler, Georgina V ^a   Kutzler, Lydia ^a   Brucklacher, Robert M ^a   Bronson, Sarah K ^a   Kimball, Scot R ^a   Freeman, Willard M ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CRYSTALLIN; BETA CRYSTALLIN; DIAZEPAM BINDING INHIBITOR; FIBROBLAST GROWTH FACTOR 2; GALECTIN 3; LIPOCORTIN 5; MESSENGER RNA; STAT3 PROTEIN; EYE PROTEIN; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; INFLAMMATION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEOMICS; QUANTITATIVE STUDY; RAT; SIGNAL TRANSDUCTION; TWO DIMENSIONAL GEL ELECTROPHORESIS; ANIMAL; BIOSYNTHESIS; CHEMISTRY; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION PROFILING; GLUCOSE BLOOD LEVEL; METABOLISM; METHODOLOGY; RETINA;

ANIMALIA; RATTUS;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; EYE PROTEINS; GENE EXPRESSION PROFILING; INSULIN; PROTEOMICS; RATS; RETINA; RNA, MESSENGER;

EID: 79251579038     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016271     Document Type: Article

References (86)

1. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE (2008) The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 115: 1859-1868.
2. Amos AF, McCarty DJ, Zimmet P (1997) The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 14 Suppl 5: S1-85.
3. Aiello LM (1998) Preserving human vision: eliminating blindness from diabetes mellitus. J Am Optom Assoc 69: 690-692.
4. Davis MD, Fisher MR, Gangnon RE, Barton F, Aiello LM, et al. (1998) Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 39: 233-252.
5. Frost-Larsen K, Larsen HW, Simonsen SE (1981) Value of electroretinography and dark adaptation as prognostic tools in diabetic retinopathy. Dev Ophthalmol 2: 222-234.
6. Hyvarinen L, Laurinen P, Rovamo J (1983) Contrast sensitivity in evaluation of visual impairment due to diabetes. Acta Ophthalmol (Copenh) 61: 94-101.
7. Sokol S, Moskowitz A, Skarf B, Evans R, Molitch M, et al. (1985) Contrast sensitivity in diabetics with and without background retinopathy. Arch Ophthalmol 103: 51-54.
8. Di Leo MA, Caputo S, Falsini B, Porciatti V, Greco AV, et al. (1994) Presence and further development of retinal dysfunction after 3-year follow up in IDDM patients without angiographically documented vasculopathy. Diabetologia 37: 911-916.
9. Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26: 275-278.
10. Cheung N, Mitchell P, Wong TY (2010) Diabetic retinopathy. Lancet 376: 124-136.
11. Barber AJ, Antonetti DA, Gardner TW (2000) Altered expression of retinal occludin and glial fibrillary acidic protein in experimental diabetes. The Penn State Retina Research Group. Invest Ophthalmol Vis Sci 41: 3561-3568.
12. Freeman WM, Bixler GV, Brucklacher RM, Lin CM, Patel KM, et al. (2010) A multistep validation process of biomarkers for preclinical drug development. Pharmacogenomics J 10: 385-395.
13. VanGuilder HD, Brucklacher RM, Patel K, Ellis RW, Freeman WM, et al. (2008) Diabetes downregulates presynaptic proteins and reduces basal synapsin I phosphorylation in rat retina. Eur J Neurosci 28: 1-11.
14. Brucklacher RM, Patel KM, VanGuilder HD, Bixler GV, Barber AJ, et al. (2008) Whole genome assessment of the retinal response to diabetes reveals a progressive neurovascular inflammatory response. BMC Med Genomics 1: 26.
15. Freeman WM, Bixler GV, Brucklacher RM, Walsh E, Kimball SR, et al. (2009) Transcriptomic comparison of the retina in two mouse models of diabetes. J Ocul Biol Dis Infor 2: 202-213.
16. Gao BB, Chen X, Timothy N, Aiello LP, Feener EP (2008) Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy. J Proteome Res 7: 2516-2525.
17. Gao BB, Clermont A, Rook S, Fonda SJ, Srinivasan VJ, et al. (2007) Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med 13: 181-188.
18. Garcia-Ramirez M, Canals F, Hernandez C, Colome N, Ferrer C, et al. (2007) Proteomic analysis of human vitreous fluid by fluorescence-based difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy. Diabetologia 50: 1294-1303.
19. Kim T, Kim SJ, Kim K, Kang UB, Lee C, et al. (2007) Profiling of vitreous proteomes from proliferative diabetic retinopathy and nondiabetic patients. Proteomics 7: 4203-4215.
20. Simo R, Higuera M, Garcia-Ramirez M, Canals F, Garcia-Arumi J, et al. (2008) Elevation of apolipoprotein A-I and apolipoprotein H levels in the vitreous fluid and overexpression in the retina of diabetic patients. Arch Ophthalmol 126: 1076-1081.
21. Garcia-Ramirez M, Hernandez C, Villarroel M, Canals F, Alonso MA, et al. (2009) Interphotoreceptor retinoid-binding protein (IRBP) is downregulated at early stages of diabetic retinopathy. Diabetologia 52: 2633-2641.
22. Quin GG, Len AC, Billson FA, Gillies MC (2007) Proteome map of normal rat retina and comparison with the proteome of diabetic rat retina: new insight in the pathogenesis of diabetic retinopathy. Proteomics 7: 2636-2650.
23. Fort PE, Freeman WM, Losiewicz MK, Singh RS, Gardner TW (2009) The retinal proteome in experimental diabetic retinopathy: up-regulation of crystallins and reversal by systemic and periocular insulin. Mol Cell Proteomics 8: 767-779.
24. Liu S, Zhang Y, Xie X, Hu W, Cai R, et al. (2007) Application of twodimensional electrophoresis in the research of retinal proteins of diabetic rat. Cell Mol Immunol 4: 65-70.
25. Gao BB, Phipps JA, Bursell D, Clermont AC, Feener EP (2009) Angiotensin AT1 receptor antagonism ameliorates murine retinal proteome changes induced by diabetes. J Proteome Res 8: 5541-5549.
26. Wu WW, Wang G, Baek SJ, Shen RF (2006) Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF. J Proteome Res 5: 651-658.
27. Vignali DA (2000) Multiplexed particle-based flow cytometric assays. J Immunol Methods 243: 243-255.
28. Unlu M, Morgan ME, Minden JS (1997) Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 18: 2071-2077.
29. Choe L, D'Ascenzo M, Relkin NR, Pappin D, Ross P, et al. (2007) 8-plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease. Proteomics 7: 3651-3660.
30. Gerhardinger C, Costa MB, Coulombe MC, Toth I, Hoehn T, et al. (2005) Expression of acute-phase response proteins in retinal Muller cells in diabetes. Invest Ophthalmol Vis Sci 46: 349-357.
31. Ying X, Zhang J, Wang Y, Wu N, Wang Y, et al. (2008) Alpha-crystallin protected axons from optic nerve degeneration after crushing in rats. J Mol Neurosci 35: 253-258.
32. Shin JH, Kim SW, Lim CM, Jeong JY, Piao CS, et al. (2009) alphaB-crystallin suppresses oxidative stress-induced astrocyte apoptosis by inhibiting caspase-3 activation. Neurosci Res 64: 355-361.
33. Munemasa Y, Kwong JM, Caprioli J, Piri N (2009) The role of alphaA- and alphaB-crystallins in the survival of retinal ganglion cells after optic nerve axotomy. Invest Ophthalmol Vis Sci 50: 3869-3875.
34. Andley UP (2007) Crystallins in the eye: Function and pathology. Prog Retin Eye Res 26: 78-98.
35. Andley UP (2008) The lens epithelium: focus on the expression and function of the alpha-crystallin chaperones. Int J Biochem Cell Biol 40: 317-323.
36. Sinha D, Klise A, Sergeev Y, Hose S, Bhutto IA, et al. (2008) betaa3/A1- crystallin in astroglial cells regulates retinal vascular remodeling during development. Mol Cell Neurosci 37: 85-95.
37. Kumar PA, Haseeb A, Suryanarayana P, Ehtesham NZ, Reddy GB (2005) Elevated expression of alphaA- and alphaB-crystallins in streptozotocin-induced diabetic rat. Arch Biochem Biophys 444: 77-83.
38. Oikari S, Ahtialansaari T, Huotari A, Kiehne K, Folsch UR, et al. (2008) Effect of medium- and long-chain fatty acid diets on PPAR and SREBP-1 expression and glucose homeostasis in ACBP-overexpressing transgenic rats. Acta Physiol (Oxf) 194: 57-65.
39. Costa E, Guidotti A (1991) Diazepam binding inhibitor (DBI): a peptide with multiple biological actions. Life Sci 49: 325-344.
40. Barmack NH, Bilderback TR, Liu H, Qian Z, Yakhnitsa V (2004) Activitydependent expression of acyl-coenzyme a-binding protein in retinal muller glial cells evoked by optokinetic stimulation. J Neurosci 24: 1023-1033.
41. Qian Z, Bilderback TR, Barmack NH (2008) Acyl coenzyme A-binding protein (ACBP) is phosphorylated and secreted by retinal Muller astrocytes following protein kinase C activation. J Neurochem 105: 1287-1299.
42. Knudsen J, Nielsen M (1990) Diazepam-binding inhibitor: a neuropeptide and/ or an acyl-CoA ester binding protein? Biochem J 265: 927-929.
43. Knudsen J, Mandrup S, Rasmussen JT, Andreasen PH, Poulsen F, et al. (1993) The function of acyl-CoA-binding protein (ACBP)/diazepam binding inhibitor (DBI). Mol Cell Biochem 123: 129-138.
44. Bormann J (1991) Electrophysiological characterization of diazepam binding inhibitor (DBI) on GABAA receptors. Neuropharmacology 30: 1387-1389.
45. Lazzarini R, Sakai M, Costa-Pinto FA, Palermo-Neto J (2010) Diazepam decreases leukocyte-endothelium interactions in situ. Immunopharmaco Immunotoxicol 32: 402-409.
46. Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, et al. (2001) Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 158: 147-152.
47. Hansen HO, Andreasen PH, Mandrup S, Kristiansen K, Knudsen J (1991) Induction of acyl-CoA-binding protein and its mRNA in 3T3-L1 cells by insulin during preadipocyte-to-adipocyte differentiation. Biochem J 277(Pt 2): 341-344.
48. Compere V, Lanfray D, Castel H, Morin F, Leprince J, et al. (2010) Acute food deprivation reduces expression of diazepam-binding inhibitor, the precursor of the anorexigenic octadecaneuropeptide ODN, in mouse glial cells. J Mol Endocrinol 44: 295-299.
49. Brachvogel B, Welzel H, Moch H, von der MK, Hofmann C, et al. (2001) Sequential expression of annexin A5 in the vasculature and skeletal elements during mouse development. Mech Dev 109: 389-393.
50. Gotow T, Sakata M, Funakoshi T, Uchiyama Y (1996) Preferential localization of annexin V to the axon terminal. Neuroscience 75: 507-521.
51. Anderson NL, Polanski M, Pieper R, Gatlin T, Tirumalai RS, et al. (2004) The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 3: 311-326.
52. Zaunreiter M, Brandstatter R, Donato R, Hermann A (2005) Localisation of annexins in the retina of the rainbow trout-light and electron microscopical investigations. Brain Res 1032: 1-10.
53. Fernandez E, Collins MO, Uren RT, Kopanitsa MV, Komiyama NH, et al. (2009) Targeted tandem affinity purification of PSD-95 recovers core postsynaptic complexes and schizophrenia susceptibility proteins. Mol Syst Biol 5: 269.
54. Kirwin SJ, Kanaly ST, Linke NA, Edelman JL (2009) Strain-dependent increases in retinal inflammatory proteins and photoreceptor FGF-2 expression in streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci 50: 5396-5404.
55. Lowe WL, Jr., Florkiewicz RZ, Yorek MA, Spanheimer RG, Albrecht BN (1995) Regulation of growth factor mRNA levels in the eyes of diabetic rats. Metabolism 44: 1038.
56. Campochiaro PA, Chang M, Ohsato M, Vinores SA, Nie Z, et al. (1996) Retinal degeneration in transgenic mice with photoreceptor-specific expression of a dominant-negative fibroblast growth factor receptor. J Neurosci 16: 1679-1688.
57. Bartoli M, Al-Shabrawey M, Labazi M, Behzadian MA, Istanboli M, et al. (2009) HMG-CoA reductase inhibitors (statin) prevents retinal neovascularization in a model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 50: 4934-4940.
58. Kim HW, Kim JL, Lee HK, Hur DY, Yun IH, et al. (2009) Enalapril alters expression of key growth factors in experimental diabetic retinopathy. Curr Eye Res 34: 976-987.
59. MacKinnon AC, Farnworth SL, Hodkinson PS, Henderson NC, Atkinson KM, et al. (2008) Regulation of alternative macrophage activation by galectin-3. J Immunol 180: 2650-2658.
60. Chu TJ, Peters DG (2008) Serial analysis of the vascular endothelial transcriptome under static and shear stress conditions. Physiol Genomics 34: 185-192.
61. Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, et al. (1995) Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1: 634-646.
62. Stitt AW, McGoldrick C, Rice-McCaldin A, McCance DR, Glenn JV, et al. (2005) Impaired retinal angiogenesis in diabetes: role of advanced glycation end products and galectin-3. Diabetes 54: 785-794.
63. Canning P, Glenn JV, Hsu DK, Liu FT, Gardiner TA, et al. (2007) Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes. Exp Diabetes Res 2007: 51837.
64. Stitt AW, Curtis TM (2005) Advanced glycation and retinal pathology during diabetes. Pharmacol Rep 57 Suppl: 156-168.
65. Pugliese G, Pricci F, Leto G, Amadio L, Iacobini C, et al. (2000) The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression. Diabetes 49: 1249-1257.
66. Henderson NC, Sethi T (2009) The regulation of inflammation by galectin-3. Immunol Rev 230: 160-171.
67. Denko CW (1979) Protective role of ceruloplasmin in inflammation. Agents Actions 9: 333-336.
68. Deshmukh VK, Raman PH, Dhuley JN, Naik SR (1985) Role of ceruloplasmin in inflammation: increased serum ceruloplasmin levels during inflammatory conditions and its possible relationship with anti-inflammatory agents. Pharmacol Res Commun 17: 633-642.
69. Barber EF, Cousins RJ (1987) Induction of ceruloplasmin synthesis by retinoic acid in rats: influence of dietary copper and vitamin A status. J Nutr 117: 1615-1622.
70. Daimon M, Susa S, Yamatani K, Manaka H, Hama K, et al. (1998) Hyperglycemia is a factor for an increase in serum ceruloplasmin in type 2 diabetes. Diabetes Care 21: 1525-1528.
71. Cunningham J, Leffell M, Mearkle P, Harmatz P (1995) Elevated plasma ceruloplasmin in insulin-dependent diabetes mellitus: evidence for increased oxidative stress as a variable complication. Metabolism 44: 996-999.
72. Tajima K, Kawanami T, Nagai R, Horiuchi S, Kato T (1999) Hereditary ceruloplasmin deficiency increases advanced glycation end products in the brain. Neurology 53: 619-622.
73. Yang LP, Sun HL, Wu LM, Guo XJ, Dou HL, et al. (2009) Baicalein reduces inflammatory process in a rodent model of diabetic retinopathy. Invest Ophthalmol Vis Sci 50: 2319-2327.
74. Masuzawa K, Jesmin S, Maeda S, Zaedi S, Shimojo N, et al. (2006) Effect of endothelin dual receptor antagonist on VEGF levels in streptozotocin-induced diabetic rat retina. Exp Biol Med (Maywood) 231: 1090-1094.
75. Joussen AM, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, et al. (2002) Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 16: 438-440.
76. Chan PS, Kanwar M, Kowluru RA (2010) Resistance of retinal inflammatory mediators to suppress after reinstitution of good glycemic control: novel mechanism for metabolic memory. J Diabetes Complications 24: 55-63.
77. Kowluru RA, Odenbach S (2004) Role of interleukin-1beta in the development of retinopathy in rats: effect of antioxidants. Invest Ophthalmol Vis Sci 45: 4161-4166.
78. Frank RN (2009) Metabolic memory in diabetes is true long-term memory. Arch Ophthalmol 127: 330-331.
79. White NH, Sun W, Cleary PA, Danis RP, Davis MD, et al. (2008) Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 126: 1707-1715.
80. Freeman WM, VanGuilder HD, Bennett C, Sonntag WE (2009) Cognitive performance and age-related changes in the hippocampal proteome. Neuroscience 159: 183-195.
81. VanGuilder HD, Yan H, Farley JA, Sonntag WE, Freeman WM (2010) Aging alters the expression of neurotransmission-regulating proteins in the hippocampal synaptoproteome. J Neurochem 113: 1577-1588.
82. Taylor CF, Paton NW, Lilley KS, Binz PA, Julian RK, Jr., et al. (2007) The minimum information about a proteomics experiment (MIAPE). Nat Biotechnol 25: 887-893.
83. Umstead TM, Lu CJ, Freeman WM, Myers JL, Clark JB, et al. (2010) Dualplatform proteomics study of plasma biomarkers in pediatric patients undergoing cardiopulmonary bypass. Pediatr Res 67: 641-649.
84. Tang WH, Shilov IV, Seymour SL (2008) Nonlinear fitting method for determining local false discovery rates from decoy database searches. J Proteome Res 7: 3661-3667.
85. Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, et al. (2009) NCBI GEO: archive for high-throughput functional genomic data. Nucleic Acids Res 37: D885-D890.
86. Allison DB, Cui X, Page GP, Sabripour M (2006) Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet 7: 55-65.